Biotech Values

[DewDiligence]

Correction to msg #63339: the third paragraph of my annotations at the top should read:

“The table below breaks down the data according to whether a patient had a non-response (hardest to retreat), viral breakthrough (intermediate), or relapse (easiest to retreat) in the first-line setting.”

In the original post, it erroneously said that viral breakthroughs were easier to retreat than relapses.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”